Low doses of ketazolam in <font color="blue">anxiety_2</font> <font color="blue">:_2</font> a double - blind , placebo - controlled study . 
<br>
<br> <font color="blue">A_1</font> <font color="blue">multicenter_1</font> <font color="blue">,_1</font> <font color="blue">double_1</font> <font color="blue">-_1</font> <font color="blue">blind_1</font> <font color="blue">,_1</font> <font color="blue">between_1</font> <font color="blue">-_1</font> <font color="blue">patient_1</font> <font color="blue">trial_1</font> <font color="blue">comparing_1</font> <font color="blue">two_1</font> <font color="blue">doses_1</font> <font color="blue">of_1</font> <font color="blue">ketazolam_1</font> <font color="blue">(_1</font> <font color="blue">15_1</font> <font color="blue">and_1</font> <font color="blue">30_1</font> <font color="blue">mg_1</font> <font color="blue">)_1</font> <font color="blue">with_1</font> <font color="blue">placebo_1</font> <font color="blue">,_1</font> <font color="blue">each_1</font> <font color="blue">given_1</font> <font color="blue">once_1</font> <font color="blue">daily_1</font> <font color="blue">,_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">evening_1</font> <font color="blue">,_1</font> <font color="blue">to_1</font> <font color="blue">92_6</font> <font color="blue">outpatients_6</font> <font color="blue">affected_6</font> <font color="blue">by_6</font> <font color="blue">generalized_6</font> <font color="blue">anxiety_6</font> <font color="blue">disorders_6</font> <font color="blue">for_5</font> <font color="blue">at_5</font> <font color="blue">least_5</font> <font color="blue">1_5</font> <font color="blue">month_5</font> <font color="blue">,_5</font> was carried out . After 1-week washout period <font color="blue">47_2</font> <font color="blue">patients_2</font> <font color="blue">were_1</font> <font color="blue">randomized_1</font> <font color="blue">to_1</font> <font color="blue">ketazolam_1</font> <font color="blue">15_1</font> <font color="blue">mg_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">45_1</font> <font color="blue">to_1</font> <font color="blue">placebo_1</font> for 15 days ( first period ) . At the end of this period , if the patient experienced a decrease on the total Hamilton Anxiety Rating Scale ( HAM - A ) of at least 25% of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) . Anxiety was rated after 2 and 4 weeks with the Italian HAM - A scale and with a 4-point scale ( patient 's assessment ) . <font color="blue">Seventy_3</font> <font color="blue">-_3</font> <font color="blue">eight_3</font> <font color="blue">patients_3</font> <font color="blue">completed_2</font> <font color="blue">the_2</font> <font color="blue">first_2</font> <font color="blue">period_2</font> <font color="blue">and_2</font> <font color="blue">75_2</font> <font color="blue">the_2</font> <font color="blue">whole_2</font> <font color="blue">study_2</font> <font color="blue">._2</font> During the first period the percentage of responders was almost identical in both treatment groups , but during the second period a further slight improvement was observed in the early placebo responders , while the HAM - A score of patients on ketazolam continued to improve significantly ( p less than 0.01 ) throughout the study . Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the 4-point scale , in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) . Tolerability was good , except in 1 patient on placebo , who was withdrawn from the study because of severe headache .